Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 5/20 | 0.48 |
| ▸ | HTR6 | P50406 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13724889 | 0.79 | CYP3A4 (0.39) | SIGMAR1HTR2CALDH1A1 | |
| SCHEMBL10988298 | 0.79 | SIGMAR1 (0.53) | SIGMAR1HTR2CHTR6HTR2AALDH1A1 | |
| SCHEMBL893700 | 0.75 | — | — | |
| SCHEMBL3458436 | 0.74 | RXRA (0.39) | HTR2CALDH1A1 | |
| SCHEMBL28559478 | 0.71 | ALDH1A1 (0.53) | SIGMAR1HTR2CALDH1A1 | |
| SCHEMBL2173351 | 0.68 | SIGMAR1 (0.65) | SIGMAR1HTR2CHTR6HTR2AALDH1A1 | |
| SCHEMBL415545 | 0.67 | SIGMAR1 (1.00) | SIGMAR1HTR2CHTR6HTR2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL10354116 | 0.67 | HTR2C (0.67) | SIGMAR1HTR2CHTR6HTR2AALDH1A1 | |
| SCHEMBL2172089 | 0.65 | SIGMAR1 (0.40) | SIGMAR1HTR2CALDH1A1 | |
| SCHEMBL14085313 | 0.65 | SIGMAR1 (0.61) | SIGMAR1HTR2CHTR6HTR2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE41998-E1 | Compositions and methods of treatment of sympathetically maintained pain | Arclon Therapeutics, Inc. (US) | 2010-12-14 | — | — | US | claimed |
| EP-1196403-B1 | ANTIPSYCHOTIC CYCLIC N-ARALKYL AMINES | SANOFI AVENTIS (FR) | 2005-11-09 | — | — | EP | claimed |
| JP-2003503487-A | — | — | 2003-01-28 | — | — | JP | claimed |
| EP-1196403-A1 | ANTIPSYCHOTIC CYCLIC N-ARALKYL AMINES | Sanofi-Aventis (FR) | 2002-04-17 | — | — | EP | claimed |
| US-20010034444-A1 | Certain bridged 4-phenyl-2-aminomethylimidazoles; new dopamine receptor subtype specific ligands | NEUROGEN CORPORATION | 2001-10-25 | — | — | US | claimed |
| US-6211366-B1 | PSYCHOLOGICAL, NERVOUS SYSTEM DISORDERS | NEUROGEN CORPORATION | 2001-04-03 | — | — | US | claimed |
| WO-2001002380-A1 | ANTIPSYCHOTIC CYCLIC N-ARALKYL AMINES | SANOFI-SYNTHELABO (FR) | 2001-01-11 | — | — | WO | claimed |
| US-5789410-A | TREATMENT OF SCHIZOPHRENIA, DEPRESSION, PARKINSON'S DISEASE | NEUROGEN CORPORATION (US) | 1998-08-04 | — | — | US | claimed |
| US-5773616-A | NEUROTROPSYCHOLOGICAL FOR SCHIZOPHRENIA AND ANTIDEPRESSANTS | NEUROGEN CORPORATION (US) | 1998-06-30 | — | — | US | claimed |
| US-4556656-A | HYPOTENSIVE, ANTIPSYCHOTIC, DIABETIC, AND ANALGESIC AGENTS | THE UPJOHN COMPANY (US) | 1985-12-03 | — | — | US | claimed |
| US-4487774-A | Isochromans | THE UPJOHN COMPANY (US) | 1984-12-11 | — | — | US | claimed |
| US-4006232-A | Therapeutic method of treating cardiac arrhythmias utilizing 3-substituted diphenylhydantoins | MILES LABORATORIES, INC. (US) | 1977-02-01 | — | — | US | claimed |
| US-8853243-B2 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORPORATION (US) | 2014-10-07 | — | — | US | disclosed |
| US-20110224189-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | INCYTE CORPORATION | 2011-09-15 | — | — | US | disclosed |
| EP-2264030-A1 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | Incyte Corporation (US) | 2010-12-22 | — | — | EP | disclosed |
| CN-1898234-A | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORP (US) | 2007-01-17 | — | — | CN | disclosed |
| EP-0160436-A2 | N-[(Amino)Alkyl]-1-pyrrolidine, 1-piperidine and 1-homopiperidinecarboxamides (and thiocarboxamides) with sulphur linked substitution in the 2, 3 or 4-position | A.H. ROBINS COMPANY, INCORPORATED (US) | 1985-11-06 | — | — | EP | disclosed |
| US-4006232-A | Therapeutic method of treating cardiac arrhythmias utilizing 3-substituted diphenylhydantoins | MILES LABORATORIES, INC. (US) | 1977-02-01 | — | — | US | disclosed |
| US-4006232-A | Therapeutic method of treating cardiac arrhythmias utilizing 3-substituted diphenylhydantoins | MILES LABORATORIES, INC. (US) | 1977-02-01 | — | — | US | disclosed |
| US-3892748-A | 5,5-Diphenyl-3-(piperidino, tetrahydropyridyl-1-and piperazino)-hydantoins | MILES LAB | 1975-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224189-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | MMP25, MMP14, MMP9 | SIGMAR1 3327/4885HTR2C 2401/4885HTR6 1891/4885 |
| US-20010034444-A1 | Certain bridged 4-phenyl-2-aminomethylimidazoles; new dopamine receptor subtype specific ligands | DBH, XDH, DRD2 | SIGMAR1 14/4885HTR2C 26/4885HTR6 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.